ArticleProstate cancer and prostatic diseases2022
Survival by race in men with chemotherapy-naive enzalutamide- or abiraterone-treated metastatic castration-resistant prostate cancer.
Article in Prostate cancer and prostatic diseases, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 5 syntheses or guidelines pooled it, 31 citations in OpenAlex.
- Equity and Cancer Survival Among Veterans Health Administration Patients: A Systematic Review and Meta-Analysis.JAMA network open · 2026Pooled it
- [Comorbidities affecting abiraterone treatment in patients with metastatic castration-resistant prostate cancer: a meta- analysis].Magyar onkologia · 2026Pooled it
- Prostate cancer metastasis and health disparities: a systematic review.Prostate cancer and prostatic diseases · 2024Pooled it
- The impact of race on survival in metastatic prostate cancer: a systematic literature review.Prostate cancer and prostatic diseases · 2023Pooled it
- Pooled it
- Trial
- Assessing racial differences in time to subsequent treatment following androgen deprivation therapy among Veterans with prostate cancer.Prostate cancer and prostatic diseases · 2026Article
- Clinical outcomes of lutetium-177-PSMA-617 in a racially diverse cohort of patients with metastatic castration-resistant prostate cancer.The oncologist · 2026Article
- Real-world analyses of major adverse cardiovascular events and mortality risk after androgen deprivation therapy initiation in black vs. white prostate cancer patients.Prostate cancer and prostatic diseases · 2025Article
- Race and Outcomes to [Cancers · 2025Article
- Real-world effectiveness of darolutamide in metastatic castration-resistant prostate cancer.Endocrine-related cancer · 2025Article
- HSD3B1, prostate cancer mortality and modifiable outcomes.Nature reviews. Urology · 2025Review
- Genetic ancestry concordant RNA splicing in prostate cancer involves oncogenic genes and associates with recurrence.NPJ precision oncology · 2025Article
- Real-world overall survival with abiraterone acetate versus enzalutamide in chemotherapy-naïve patients with metastatic castration-resistant prostate cancer.Prostate cancer and prostatic diseases · 2024Article
- Emerging racial disparities among Medicare beneficiaries and Veterans with metastatic castration-sensitive prostate cancer.Prostate cancer and prostatic diseases · 2024Article
- Racial and Ethnic Differences in Prostate Cancer Epidemiology Across Disease States in the VA.JAMA network open · 2024Article
- Association between concomitant proton pump inhibitor use and survival of patients with metastatic prostate cancer receiving abiraterone acetate: a post-hoc analysis of pooled data from three randomized controlled trials.Prostate cancer and prostatic diseases · 2024Article
- Evaluation of Survival Outcomes Among Black and White Patients with Metastatic Castration-resistant Prostate Cancer: A Systematic Review and Meta-analysis.European urology open science · 2024Article
- Disparities With Systemic Therapies for Black Men Having Advanced Prostate Cancer: Where Do We Stand?Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2024Review
- Impact of different visceral metastatic sites on survival in metastatic prostate cancer patients.PloS one · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 6 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundBlack men are more likely to be diagnosed with aggressive prostate cancer (PC) and die from PC than white men. However, black men with metastatic castration-resistant PC (mCRPC) had longer overall survival (OS) than white men when treated with certain agents in clinical trials. We analyzed claims data from the Veterans Health Administration (VHA) database to evaluate OS in black and white men treated with enzalutamide or abiraterone (novel hormonal therapy [NHT]) for chemotherapy-naïve mCRPC.
methodsPatients with mCRPC aged ≥18 years were identified in the VHA database by diagnosis codes, evidence of surgical/medical castration, and a prescription claim for enzalutamide or abiraterone after castration from April 2014-March 2017. Cox models assessed associations between race and OS. Unadjusted and multivariable analyses were performed on the entire population and subsets based on the type of therapy received (if any) after NHT.
resultsIn total, 2910 patients were identified (787 black, mean 71.7 years; 2123 white, mean 74.0 years). Median follow-up was 19.0 and 18.7 months in blacks and whites, respectively. Black men had better survival versus white men: hazard ratios (95% CIs) were 0.89 (0.790-0.996; P = 0.044) and 0.67 (0.592-0.758; P < 0.0001) in the unadjusted and multivariable models, respectively. Statistically significantly longer OS was seen in black versus white men regardless of subsequent treatment, including no subsequent treatment.
conclusionsIn the VHA, black men with chemotherapy-naïve mCRPC initiating NHT may have better outcomes than similarly treated white men.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.